journal article·2017-04-20

Combined Experimental and Computational Study of the In Situ Adsorption of Piroxicam Anions on the Laser-Generated Gold Nanoparticles

Roya Binaymotlagh, Hossein Farrokhpour, Hassan Hadadzadeh, Seyede Zohreh Mirahmadi-Zare, Zahra Amirghofran

The Journal of Physical Chemistry C· Volume 121· Issue 15
Publisher page

Abstract

Gold nanoparticle–piroxicam anion conjugates (Au NP–Pir) were synthesized in a green method using laser ablation of a gold foil in an aqueous solution of anionic piroxicam (NaPir). The produced Au NP–Pir conjugates were characterized by different spectroscopic techniques and transmission electron microscopy. The fluorescence and absorption spectra of Au NP–Pir colloidal solution were recorded at different concentrations of the Au NPs to investigate the effect of conjugation on the spectral properties of both the free Pir anion and Au NPs. Comparing the FT-IR spectrum of the colloidal solution of Au NP–Pir with that of the solution of the free Pir anion indicates that this anion binds to the surface of Au NPs through its different binding sites, viz., the pyridyl nitrogen atom, the SO 2 group, and the amide oxygen atom. To support the experimental observations, theoretical calculations were also performed to evaluate the interaction of different binding sites of Pir with one Au atom and the effect of this interaction on the IR spectrum of Pir. In a more realistic theoretical study, the optimized geometry of Pir on the Au(111) surface was calculated, and its orientation toward the surface of Au was obtained. The calculations show that the pyridyl ring of Pir prefers to orient perpendicular to the surface of Au, and the O atoms of the SO 2 and amide groups are responsible for the interaction with the surface. The cytotoxic effect of the free Pir anion and Au NP–Pir conjugates against the Jurkat T-cells was studied using an MTT assay. The results show that only the Au NP–Pir conjugates have significant anticancer activity against the Jurkat T-cells with an IC 50 value of 33.8 ± 2 μg/mL. In comparison with the pure Au NPs and free Pir, the Au NP–Pir conjugates show a significant antimicrobial activity against two pathogens including Gram-negative Escherichia coli ( E. coli ) and Gram-positive Staphylococcus aureus ( S. aureus ).
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Laser-Ablation Synthesis of Nanoparticles · Gold and Silver Nanoparticles Synthesis and Applications · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Iran

Department of Molecular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Funding

Royan Institute · Isfahan University of Technology

References (83)

Show source-provided references
1. 10.1039/c3ra44578j10.1039/c3ra44578j ↗
2. 10.1016/j.molstruc.2012.04.09410.1016/j.molstruc.2012.04.094 ↗
3. 10.1093/carcin/21.3.52510.1093/carcin/21.3.525 ↗
4. 10.1093/carcin/20.1.5110.1093/carcin/20.1.51 ↗
5. 10.1093/carcin/21.5.40310.1093/carcin/21.5.403 ↗
6. 10.1093/carcin/19.12.219510.1093/carcin/19.12.2195 ↗
7. 10.1016/j.ica.2013.09.03510.1016/j.ica.2013.09.035 ↗
8. Cho C. W. · Iran. J. Pharm. Res. · 2011 · 110 · 3
9. 10.1023/A:102036721230710.1023/A:1020367212307 ↗
10. 10.1111/j.1939-1676.1994.tb03232.x10.1111/j.1939-1676.1994.tb03232.x ↗
11. 10.1016/S0167-4889(97)00140-710.1016/S0167-4889(97)00140-7 ↗
12. Harris R. E. · Cancer Res. · 2000 · 60 · 2101
13. 10.1111/j.1748-5827.2006.00006.x10.1111/j.1748-5827.2006.00006.x ↗
14. 10.1016/j.jinorgbio.2006.03.00610.1016/j.jinorgbio.2006.03.006 ↗
15. 10.1016/j.ijpharm.2015.05.03210.1016/j.ijpharm.2015.05.032 ↗
16. 10.1016/j.proeng.2013.10.00410.1016/j.proeng.2013.10.004 ↗
17. 10.1158/0008-5472.CAN-08-146810.1158/0008-5472.CAN-08-1468 ↗
18. 10.1016/j.micromeso.2012.08.01010.1016/j.micromeso.2012.08.010 ↗
19. 10.1021/cr030698+10.1021/cr030698+ ↗
20. 10.1016/j.nano.2010.09.00110.1016/j.nano.2010.09.001 ↗
21. 10.1039/c2ra20386c10.1039/c2ra20386c ↗
22. 10.2174/138920021566614060513142710.2174/1389200215666140605131427 ↗
23. 10.1016/j.msec.2013.09.00410.1016/j.msec.2013.09.004 ↗
24. 10.1039/b914071a10.1039/b914071a ↗
25. 10.1007/s13404-011-0015-810.1007/s13404-011-0015-8 ↗
26. 10.1039/C5CP02717A10.1039/C5CP02717A ↗
27. 10.1021/ic202197g10.1021/ic202197g ↗
28. 10.1021/la035856710.1021/la0358567 ↗
29. 10.1126/science.257.5073.106410.1126/science.257.5073.1064 ↗
30. 10.1021/nn504262510.1021/nn5042625 ↗
31. 10.1021/nl034396z10.1021/nl034396z ↗
32. 10.1002/adfm.20080152610.1002/adfm.200801526 ↗
33. 10.1016/j.eiar.2004.06.00610.1016/j.eiar.2004.06.006 ↗
34. 10.1021/jp109281q10.1021/jp109281q ↗
35. 10.1016/j.matchemphys.2016.04.04010.1016/j.matchemphys.2016.04.040 ↗
36. 10.1002/jrs.483910.1002/jrs.4839 ↗
37. 10.1021/acs.jpcc.5b0783110.1021/acs.jpcc.5b07831 ↗
38. 10.1021/jp309625h10.1021/jp309625h ↗
39. 10.1039/C6RA22038J10.1039/C6RA22038J ↗
40. 10.1039/C3RA44507K10.1039/C3RA44507K ↗
41. 10.1016/j.cplett.2004.06.01110.1016/j.cplett.2004.06.011 ↗
42. 10.1039/c3cp55493g10.1039/c3cp55493g ↗
43. 10.1080/0026897700010156110.1080/00268977000101561 ↗
44. 10.1021/acs.jpca.6b0740310.1021/acs.jpca.6b07403 ↗
45. 10.1016/S0166-1280(98)00475-810.1016/S0166-1280(98)00475-8 ↗
46. Frisch M. J. · 2009
47. 10.1021/jp003709110.1021/jp0037091 ↗
48. 10.1021/ja048678s10.1021/ja048678s ↗
49. 10.1021/jp001336y10.1021/jp001336y ↗
50. 10.1021/jp001803b10.1021/jp001803b ↗
51. 10.1021/acs.jpcc.6b0016110.1021/acs.jpcc.6b00161 ↗
52. 10.1039/b900654k10.1039/b900654k ↗
53. 10.1016/j.vibspec.2004.04.00410.1016/j.vibspec.2004.04.004 ↗
54. 10.1002/jccs.20010002710.1002/jccs.200100027 ↗
55. 10.1016/j.ejmech.2013.08.05110.1016/j.ejmech.2013.08.051 ↗
56. 10.1021/acs.langmuir.6b0297610.1021/acs.langmuir.6b02976 ↗
57. 10.1039/c0cp02967j10.1039/c0cp02967j ↗
58. 10.1016/j.ab.2004.11.02610.1016/j.ab.2004.11.026 ↗
59. 10.1016/j.jpba.2010.03.03910.1016/j.jpba.2010.03.039 ↗
60. 10.1021/acs.jpcc.6b0512410.1021/acs.jpcc.6b05124 ↗
61. 10.1021/jp507086g10.1021/jp507086g ↗
62. 10.1016/j.molstruc.2008.05.00510.1016/j.molstruc.2008.05.005 ↗
63. 10.1371/journal.pone.014629710.1371/journal.pone.0146297 ↗
64. 10.1155/2010/97575610.1155/2010/975756 ↗
65. 10.1016/j.saa.2009.10.02710.1016/j.saa.2009.10.027 ↗
66. 10.1016/S0039-9140(00)00569-510.1016/S0039-9140(00)00569-5 ↗
67. 10.1039/C4AY02561J10.1039/C4AY02561J ↗
68. 10.1016/j.jpha.2013.05.00110.1016/j.jpha.2013.05.001 ↗
69. Zhang X. W. · Chem. J. Chin. Univ. · 1999 · 20 · 1063
70. 10.1039/c4ra02569e10.1039/c4ra02569e ↗
71. 10.4236/anp.2012.1300810.4236/anp.2012.13008 ↗
72. 10.1039/C4PP00223G10.1039/C4PP00223G ↗
73. 10.1039/c3tb20991a10.1039/c3tb20991a ↗
74. 10.4172/2157-7439.100013310.4172/2157-7439.1000133 ↗
75. Durig J. R. · 1972
76. 10.1021/jp108444410.1021/jp1084444 ↗
77. Hamman J. H. · Drug Target Insights · 2007 · 2 · 7110.1177/117739280700200003 ↗
78. 10.1016/j.ejps.2012.12.00610.1016/j.ejps.2012.12.006 ↗
79. 10.1080/10590501.2015.105516110.1080/10590501.2015.1055161 ↗
80. 10.4172/2167-0501.100019910.4172/2167-0501.1000199 ↗
81. 10.1021/jp063826h10.1021/jp063826h ↗
82. 10.1016/j.carres.2009.09.00110.1016/j.carres.2009.09.001 ↗
83. 10.5897/AJMR2016.801310.5897/AJMR2016.8013 ↗